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Repeated delivery of chlorhexidine chips for the treatment of periimplantitis: a multicenter, 
randomized, comparative clinical trial  
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Summary of key findings: A sizeable reduction in pocket depth could be attained in 
periimplantitis sites treated with repeated application of chlorhexidine chips.   
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Background: Periimplantitis is a challenging condition to manage and is frequently treated 
using non-surgical debridement. The local delivery of antimicrobial agents has demonstrated 
benefit in mild to moderate cases of periimplantitis. This study compared the safety and 
efficacy of Chlorhexidine gluconate 2.5 mg chip (CHX chips) as an adjunctive treatment to 
sub-gingival debridement in patients afflicted with periimplantitis. 
Methods: A multi-center, randomized, single-blind, two-arm, parallel Phase-3 study was 
conducted.  Periimplantitis patients with implant pocket depths (IPD) of 5-8 mm underwent 
sub-gingival implant surface debridement followed by repeated bi-weekly supra-gingival 
plaque removal and Chlorhexidine chips application (ChxC group) for 12 weeks, or similar 
therapy but without application of ChxC (control group). All patients were followed for 24 
weeks.  Plaque and gingival indices were measured at every visit while IPD, recession and 
bleeding on probing were assessed at 8,12,16,24 week. 
Results: 290 patients were included: 146 in the ChxC group and 144 in the control.  At 24 
weeks, a significant reduction in IPD (p=0.01) was measured in the ChxC group (1.67 ± 1.13 
mm) compared to the control group (1.54 ± 1.13 mm).  IPD reduction of ≥2 mm was found in 
59% and 47.2% of the implants in the ChxC and control groups, respectively (p=0.03). 
Changes in gingival recession (0.29 ± 0.68 mm vs. 0.15 ± 0.55 mm, p=0.015) and relative 
attachment gain (1.47 ± 1.32 mm and 1.39 ± 1.27 mm, p=0.0017) were significantly larger in 
the ChxC group.  Patients in the ChxC group that were <65 years exhibited significantly 
better responses (p<0.02); likewise, non-smokers had similarly better response (p <0.02).  
Both protocols were well tolerated, and no severe treatment-related adverse events were 
recorded throughout the study.   
Conclusions: Patients with periimplantitis that were treated with an intensive treatment 
protocol of bi-weekly supra-gingival plaque removal and local application of Chlorhexidine 
chips had greater mean IPD reduction and greater percentile of sites with IPD reduction of ≥2 
mm. as compared to bi-weekly supra-gingival plaque removal.  (Clinicaltrials.gov 
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Introduction 
Treatment strategies for periimplantitis are derived from standard treatment regimens for 
periodontitis, but the results are generally less favorable.  A Cochrane systematic review of 
the effectiveness of various treatment protocols for periimplantitis could not suggest which 
treatment modality is the most effective.
1
 However, access flap surgery was found to be 
somewhat more effective than mechanical debridement alone.  Numerous surgical procedures 
were tested with varying degree of predictability and success.  These include open flap 











 or the use of progenitor cell therapy.
7
   
In a survey among periodontists in the USA, 49.1% reported the use non-surgical 
debridement for the treatment of periimplantitis.
8
 Nonetheless, a more recent meta-analysis 
found that this modality has a significant effect on reducing bleeding on probing but not on 
pocket reduction.
9
   
The adjunctive local delivery of antibiotics/antiseptics into periimplant pockets were shown 
to enhance tissue response when compared to non-surgical debridement. In a study using 
minocycline microspheres for incipient periimplantitis sites, a small (0.6 mm), but significant 
average reduction in implants probing depth (IPD) was reported at 12 months.
10
 While in a 
similar study using doxycycline gel following mechanical debridement, a 1.15 mm reduction 
in IPD with 1.17 mm attachment level gain was reported.
11
 Likewise, local delivery of 
tetracycline in polymeric fibers yielded marked reduction in IPD at twelve months post-op.
12
   
To further enhance treatment response, an intensive protocol of Chlorhexidine chips
##1
 
(ChxC) placement was tested in periimplantitis sites; in this previously reported study, 
marked reduction in IPD (2.19 mm) and substantial attachment level gains (2.21 mm) were 
reported.
13
 However,  











This article is protected by copyright. All rights reserved. 
the moderate sample size (30 patients with 37-40 implants in each group) did not allow to 
draw definitive conclusions.   
Thus, the purpose of the present multi-center, randomized, single-blind, two-arm, parallel 
clinical trial was to assess in a large patient population, the adjunctive effect of multiple 
application of Chlorhexidine chips into the peri-implant pockets affected by periimplantitis 
after sub-gingival implant surface debridement and compare it to repeated implant surface 
debridement alone.   
 
Materials and Methods 
This study (registered at ClinicalTrials.gov, number NCT02080403) was conducted in 
accordance with the globally accepted standards of International Clinical Harmonization 
Good Clinical Practice (ICH-GCP), in agreement with the revision of the Declaration of 
Helsinki (2008) and in compliance with the protocol and all applicable local laws, guidelines 
and regulations. The study was approved by the institutional ethics committee of all ten 
participating medical centers prior to commencement (see authors affiliation in the title), files 
on record.   
Adult patients (≥18 years old), seeking treatment for periimplantitis were screened for this 
study.  To be included, these implants had to be in functioning for >2 years with fixed 
restoration and IPD of 5-8 mm, bleeding and/or suppuration on probing. In addition, implants 
were required to display radiographic evidence of bone loss of at least 3 mm from the implant 
shoulder but with at least 2 mm residual bone support.  Patients with a history of 
Chlorhexidine allergy or those who routinely use Chlorhexidine mouthwash/rinse were 
excluded.  Likewise, a horizontal distance of less than 2 mm from its neighboring tooth / 
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treated periodontitis ≤ 6 weeks post-op), presence of oral soft or hard tissue tumors and/or 
any local mechanical factors that could have acted as local etiological factors, systemic 
antibiotic therapy or prolonged treatment with non-steroidal anti-inflammatory drugs and/or 
medications known to affect hard and soft tissue conditions. Uncontrolled diabetes of any 
type (HbA1c >7.5%), post-radiation therapy to the head and neck region and 
immunosuppressive therapy were also disqualifying conditions.  
Following informed consent, eligible patients underwent full-mouth periodontal examination, 
followed by supra-gingival scaling of all teeth and implants. Baseline measurements of the 
diseased implants included IPD, bleeding on probing (BOP) and recession (R). At baseline, a 
full mouth plaque index
14
 (PI) and gingival index
15
 (GI) were recorded and supra-gingival 
plaque was removed; oral hygiene instructions, to be adhered to throughout the study, were 
provided.  At least one but no more than two implants were selected for the study (with the 
deepest IPD but not exceeding 8 mm).  Adjacent implants not included in the study were 
treated as per the investigators discretion as long as it did not affect the study 
inclusion/exclusion criteria (e.g. treatment with antibiotics or surgery next to a target implant 
included in the study.  For each study implant, 4 sites were measured: MB, B, DB, L with one 
of them defined as 'target site'.  Patients were then randomly assigned into one of the 
following treatment protocols: repeated supra-gingival plaque removal (control) or supra-
gingival plaque removal and repeated ChxC insertion, up to two chips per pocket, depending 
on pocket width (experimental).   
Randomization and concealment: Eligible patients were assigned a randomization number at 
the Baseline visit (Visit 2). Each randomization number was randomly assigned to the letter 
A or B to reflect random assignment to either treatment with chlorhexidine chip + sub-
gingival debridement or sub-gingival debridement alone, respectively.  Randomization was 
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program before the start of the study. Randomization was stratified in balanced blocks based 
on smoking habits and PD measurement at the Baseline visit, with each block containing 6 
patients (3 per treatment arm). Randomization blocks were sent to sites, such that each site 
received 4 types of lists by the defined stratification factors (ie, smokers with PD of 5 mm, 
smokers with PD of 6 to 8 mm, nonsmokers with PD of 5 mm, and nonsmokers with PD of 6 
to 8 mm). Additional blocks were provided to the sites according to the recruitment rate. 
Designated study personal at each site recorded the clinical data at each visit into the CRF.  
100% of the clinical data that was collected and recorded was verified by the Sponsor’s 
monitor. Each CRF had an investigator confirmation at the “Study Completion” form. 
In both groups, sub-gingival debridement was performed at baseline and at the last treatment 
sessions (week 12). In the first 12 weeks of the study patients were seen once every 2 weeks.  
At each visit, the above treatment protocol was repeated and PI and GI of the target implant 
were recorded; oral hygiene protocol was reinforced, and soft tissue examination was 
performed. Patients were instructed to refrain from use of Chlorhexidine-based oral rinses 
throughout the study and to avoid use of toothpicks and floss for at least 24 hours after 
treatment. At weeks 8, 12 and 16, IPD, recession and BOP were recorded, and final 
measurements were recorded at six months. Adverse events and changes in medication 
regimens were recorded at each visit.   
All the clinical measurements were performed by calibrated examiners (standardized among 
investigators at each medical center prior to study initiation).  In short, the agreement 
between the examiners (inter-observed) and between the assessments of the same examiner 
(intra observed) was evaluated using Kappa statistics.  Intra-observed reliability was 
determined by comparison of matched test and re-test data (first and second readings) for 
each examiner (where available) and was expressed as weighted Kappa coefficient with 95% 
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comparing data between pairs of examiners and was expressed as weighted Kappa coefficient 
with 95% confidence interval. Kappa values >0.61, were required.  
The data was analyzed using the SAS ® version 9.1 (or higher). All the clinical 
measurements were performed by calibrated examiners (standardized among investigators at 
each medical center prior to study initiation).   
IPD and R measurements were taken with a standard University of North Carolina (UNC) 15-
mm periodontal probe. BOP was measured (0/1) at the target implant immediately after 
measuring the IPD. Relative attachment level (RAL) was calculated by summing the R and 




Power calculation to determine the sample size was based on the findings of a previous phase 
IIa study.
13
 The Primary Efficacy Endpoint was mean probing PD reduction (absolute 
change) for the selected target implant from baseline to 24 weeks. In order to detect a mean 
inter-group PD difference of 0.50 mm, with an alpha error of 5% and 85% power, a sample 
size of 123 individuals in each group was required (assuming mean PD reduction of -2.29 
mm in the experimental group and mean PD reduction of -1.79 mm in the control group, with 
standard deviation of 1.30 mm in both groups). The Secondary efficacy endpoints included 
PD reduction, baseline to six months, for sites 6-8 mm at baseline; reduction in bleeding on 
probing (BOP) baseline to 16 and baseline to 24 weeks; and changes in PD baseline to 16 
weeks (this sample size was not powered to detect differences in any of the secondary 
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The mixed linear model was used, with treatment as the fixed factor and patient and pocket as 
random effects. The model was adjusted to baseline measure, center, age, gender and 
smoking status. The treatment-by-smoking interaction was found statistically significant (p-
value <0.05) and, therefore, was added to the model as covariate. Other post-hoc endpoints 
explored included the changes (from baseline) in recession (R) and relative attachment level 
(RAL). Statistical significance level for all analyses was set to 5%. 
Statistically significant center effect could not be established (albeit individual centers 
variation); thus, all data were grouped together for statistical analyses. Data sets analyzed 
included the modified intent-to-treat (mITT) study sample, which included all patients who 
had undergone at least one sub-gingival debridement procedure (control arm) or treated with 
at least one ChxC (experimental arm), with no major protocol violations, and the per protocol 
(PP) study sample, which included all patients who completed the study with no major 
protocol deviations and within the following allowed inter-visit time windows: no limitation 
between screening (visit 1) and baseline (visit 2); between visits 3, 4, 5, 6, 7 and 8 the 
allowance was 14+7 days or 14-4 days; between visit 8 and 9, the allowance was 28±7 days 
and  between visit 9 and 10, the allowance was 56+28 days or 56-14 days.  
 
Results 
The study was conducted between August 19, 2014 (first patient in) to June 28, 2018 (last 
patient out.  Of the 370 patients screened, 290 were found eligible and were randomized to 
one of the two study arms (experimental: n=146; control: n=144). The majority of patients 
(59%) were female, 84.1% were White, 4.45% of Black or African American descent, 91.4% 
non-Latino/Hispanic.  Age ranged from 23.8–87.4 years, mean 62.6 ± 11.4 years (Table 1).  
In total, 386 implants (experimental: n=197; control: n=189) were treated, in 10 centers 
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patients recruited (8-47) and implants treated (8-65). There were 235 implants in the maxilla 
and 151 in the mandible. Posterior implants in the molar/premolar region (322) vastly 
outnumbered the anterior one (64).  Of these, 90.7% of the patients completed the study.    
 The changes in IPD baseline to 24 weeks, as measured in the mITT (n=259 [324]) and PP 
(n=193 [263]) patients [pockets], are presented in Table 2. In the mITT sample, the 
experimental group showed a significant pocket depth reduction of 1.67 ± 1.13 mm (median 
2.0 mm), whereas a mean IPD reduction of 1.54 ± 1.13 mm (median 1.0 mm) was measured 
in the control group (p=0.0821). Greater differences were noted for the PP sample, which 
showed a mean pocket depth reduction of 1.69 ± 1.12 mm (median 2.0 mm) following the 
experimental protocol compared to 1.52 ± 1.14 mm (median 1.0 mm) in the control 
(p=0.0082).  In the mITT sample, 59.0% of the target implants in the experimental group 
versus 47.2% in the control group showed IPD reduction of ≥2 mm at week 24 (p=0.0338). In 
the PP population, 62.6% of the target implants in the experimental group versus 47.0% in 
the control group showed IPD reduction of ≥2 mm at week 24 (p=0.0109), Table 3.  Overall, 
target implants with greater initial IPD showed greater pocket reductions at week 24 (Table 
4).  More specifically, at 24 weeks, ChxC treated sites with a baseline pocket depth of 5-6 
mm displayed a mean PD reduction of 1.53 ± 0.96 mm while 7-8 mm sites showed 
significantly greater reduction (2.23 ± 1.30 mm) which was statistically significant 
(p=0.0008). Likewise, for the control these figures were lower albeit significant (1.39 ± 0.97 
versus 1.84 ± 1.38 mm, p=0.0383).  
The kinetics of IPD changes (Figure 1) showed a distinct pattern for each group, with the 
experimental group displaying a slow but steady IPD reduction after the first 8 weeks of 
treatment, followed by continuous linear improvements until week 24.  In contrast, the 
control group showed a rapid initial improvement during the first 8 weeks of treatment, 
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At baseline, 100% of the sites in both groups showed BOP at the target implant site. At 24 
weeks, approximately half of these sites had no signs of BOP (49.69% and 44.79% for the 
experimental and control groups, respectively). 
Small increases in gingival recession were noted after 24 weeks (0.29 ± 0.68 mm for the 
experimental group compared to 0.15 ± 0.55 mm for the control group, p=0.015). Relative 
attachment level gain was 1.47 ± 1.32 mm and 1.39 ± 1.27 mm for the experimental and 
control, respectively (p=0.0017) (Table 2).  
Both younger (< 65 years) and elderly (≥ 65 years) individuals responded positively and in a 
similar manner to the experimental protocol (mean IPD reduction of 1.73 ± 1.17 mm and 1.78 
± 1.09 mm, respectively).  However, when compared to the control cohort, younger 
individuals demonstrated significantly better responses to the experimental treatment (1.73 ± 
1.17 mm compared to 1.38 ± 1.13 mm; p=0.0183), Table 5.   
Due to the low percentage of smokers in the study population (10%), a meaningful sub-group 
analysis was not feasible. However, when smokers were excluded from the analysis, non-
smoking patients in the experimental group showed significantly greater mean IPD 
reductions at week 24 (1.82 ± 1.11 mm), as compared to the control non-smokers (1.53 ± 
1.14 mm), p=0.0186 (Table 5).   
Overall, both protocols were well tolerated and both treatment arms were only associated 
with mild, short-term and self-limiting adverse events (see Table S1 in online Journal of 
Periodontology).  In total, 18 patients in the experimental group and 2 patients in the control 
group, reported mild events such as pain and discomfort. One patient in the control group 
presented with swelling and sinus tract on the labial aspect of the implant, which required 
thorough sub-gingival debridement and rinsing with antiseptics.  No treatment-related severe 
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out of which 7 patients were withdrawn due to adverse events (5 in the experimental and 2 in 
the control). None of these events were found to be related to the study medication. Missing 
data was imputed for the primary endpoint data using the MMRM model (Mixed-effect 
Model for Repeated Measures) with multiple imputation, which is based on MAR (missing at 
random) assumption.  No clinically significant changes in the dental health or concomitant 




In this first ever-reported large-scale, global multicenter randomized controlled phase 3 study 
of periimplantitis, a sizable reduction in mean IPD following repeated application of ChxC 
was observed after 6 months (mean 1.79 mm., median 2.0 mm) which was significantly 
greater than control (mean 1.52 mm., median 1.0 mm).  In an earlier study, using the same 
intensive protocol in 30 patients (40 implants), a mean 2.19 mm IPD reduction was reported 
at six months.
13
 However, baseline pocket depths for that study were 6-10 mm (mean 7.60 
mm) compared with 5-8 mm (mean 6.16 mm) in the present study.  In a similar study of 17 
patients (57 implants) using repeated local minocycline application into moderate 
periimplantitis pockets, a smaller (0.71 mm) IPD reduction was reported for the experimental 
sites.
16
  More recently, in a preliminary study of similar intensive protocol and local 
application of Chlorhexidine and minocycline HCl, a 1.79 mm. reduction in IPD 6-12 months 
post-op was reported.
17
  Paolantonio et al.
18
 reported, in an in-vitro study, that treatment with 
1% Chlorhexidine in the implant-abutment connection is required to reduce the total bacterial 
count in these sites.  Hence, the repeated application of high concentration Chlorhexidine 
chips is likely to have significantly reduced the bacterial load in the periimplant pockets for 
an extended period of time. A systematic review and Bayesian network meta-analysis of 




This article is protected by copyright. All rights reserved. 




Implants in the control group had lesser, however significant IPD reduction at 6 months.  
This phenomenon might be attributed to the repeated removal of supra-gingival plaque (every 
fortnight) performed in these sites.  Treatment studies of repeated implant debridement 
therapy for periimplantitis have not been previously reported.  In a study of repeated 
(monthly) scaling or oral hygiene instruction (OHI) with or without local application of 25% 
metronidazole gel in periodontitis sites, greater reduction was observed in PD at 12 months 
for the repeated OHI (2.6 mm) and scaling (3.3 mm) with no adjunctive effect for the gel 
application.
20
  Likewise, in a clinical trial of periodontitis patients that underwent weekly 
supra-gingival plaque removal for 3 months, a marked reduction in overall bacterial load 
compatible with periodontal health was achieved at 9 months post-op.
21
  Another possible 
explanation for this phenomenon is a strong Hawthorne effect associated with the bi-weekly 
visit to the dental office, coupled with the mechanical treatment.  Similarly, strong 
Hawthorne effect was reported in orthodontic patients enrolled in a mock study compared to 
non-participant controls.
22 
 In yet another study of the predictors of placebo analgesia 
response in controlled trials of chronic pain, the number of face-to-face visits was found to be 
a strong predictor of the magnitude of response.
23
  A systematic review and meta-analysis of 
the placebo effect in ulcerative colitis studies have concluded that increase in trial duration 
and more interaction with healthcare providers increased the placebo effect.
24
   
The follow-up period designed for this study was set for six months.  Thus, the long-term 
effect of this protocol cannot be evaluated.  Other limitation associated with this study 
include the use of single rather than double blinded due to lack of placebo control; previous 
studies (Jeffcoat et al. 1998; Jeffcoat et al. 2000)
25-26
 have shown that both modalities had 
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be noted, however these were all transitory and minimal.  Also, the cost benefit ratio is a 
double edge sword: on one hand the experimental arm is costlier for the patient while on the 
other hand, the greater percentiles of sites with IPD reduction of 2 mm. or greater in the 
experimental group (62.6 versus 47%, p = 0.01) is likely to reduce the number of surgeries 
required in these implants thus improving the cost-benefit ratio (Lissovoy et al. 1999).
27
   
The experimental group exhibited slow and continuous reduction in IPD through the 6-
months observation period, whereas the control group showed greater initial reduction at 8 
weeks with only slight improvement thereafter (Fig. 1).  The same phenomenon was 
observed in a previous phase IIa study that utilized the same protocol.
13
 In contrast, Mombelli 
and co-workers,
12
 using Tetracycline fibers for the treatment of periimplantitis reported that 
the bulk of this improvement in IPD occurred in the first 30 days while only minor further 
improvements occurred over the next 6-12 months.   
Almost 2/3 of the sites treated in the experimental group displayed 2 mm or greater reduction 
in IPD compared to less than half of the sites in the control group (p<0.0338). The sizable 
proportion of sites that yielded IPD reduction of 2 mm or greater, coupled with baseline IPD 
of 5-8 mm, suggested that only few sites in the experimental group had residual IPD > 6mm 
at the conclusion of the study.  Similar results were previously reported.
13
 A multi-center 
RCT on the adjunctive effect of single application of Chlorhexidine chip in reducing PD 
around teeth, after 12 weeks, only 30.3% of the sites exhibited PPD reduction of 2 mm or 
greater.
25
 In summary, these findings suggest the value of repeated local delivery of ChxC to 
improve clinical outcomes.   
Sites with deeper initial pockets demonstrated substantially greater reduction in IPD ranging 
from 1.53 mm for the sites of 5-6 mm around implants to 2.23 mm for the 7-8 mm sites 
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1.84 mm for the 7-8 mm implants in the control, respectively.  Similarly, in a previous study 
of mechanical debridement and local application of Chlorhexidine, sites with initial IPD ≤6 
mm exhibited minimal (< 1 mm) reduction, while sites ≥7 mm at baseline resulted in 
significantly greater reduction after twelve months.
28
  Also, another study using sub-gingival 
air polishing and povidone-iodine application into periimplantitis pockets, the group reported 
1.3-1.4 mm reduction in IPD for all sites compared to 2.3 – 2.6 mm reduction in sites with 
initial IPD > 6 mm.
29
  It is therefore reasonable to assume that sites with initial IPD of 7-8 
mm are likely to benefit the most from this protocol with an anticipated mean reduction of ~ 
2 mm. That, coupled with elimination of inflammatory signs as evident in the reduction in 
BOP, might reduce the need for additional surgical treatment following this protocol in such 
periimplantitis patients.
30-31
   
In conclusion: In this large-scale multicenter RCT, periimplantitis-affected implants 
benefitted the most from a treatment protocol that included bi-weekly plaque removal and 
local application of Chlorhexidine chips.  The long-term effect of this treatment modality and 
the exact mode of action is yet to be established.   
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Figure 1. Changes in implants pocket depth compared to baseline (mITT).  Please note continuous 
improvement throughout the 6-months in the ChxC group while initial greater improvement in the 
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Age, mean ± SD (range), years 
62.5 ± 11.2 
(25.5 – 86.9) 
62.6 ± 11.6 
(23.8 – 87.4) 
Gender, n (%)   
Male 55 (37.7%) 63 (43.8%) 
Female 91 (62.3%) 81 (56.3%) 
Race, n (%)   
Asian 8 (5.5) 5 (3.5) 
Black or African American 10 (6.8) 3 (2.1) 
White 117 (80.1) 127 (88.2) 
Other 11 (7.5) 9 (6.3) 
Ethnicity, n (%)   
   NA 1 (0.7) 1 (0.7) 
   Hispanic or Latino 14 (9.6) 9 (6.3) 
   Non-Hispanic or Latino 131 (89.7) 134 (93.1) 
Smoking habits, n (%)   
 Smokers 15 (10.3%) 14 (9.7%) 
 Former Smokers 51 (34.9%) 55 (38.2%) 
 Never Smoked 80 (54.8%) 75 (52.1%) 
Dental status, mean ± SD (range)   
Number of natural teeth 
19.96 ± 6.39 
(0.00 – 30.00) 
20.41 ± 5.65 
(0.00 – 31.00) 
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4-6 mm (0.00 – 19.00)  (0.00 – 21.00) 
Number of natural teeth with IPD ≥ 7 mm 
0.21 ± 0.60 
(0.00 – 3.00) 
0.17 ± 0.45 
(0.00 – 3.00) 
Number of implant(s) 
4.21 ± 3.27 
(1.00 – 15.00) 
3.79 ± 3.00 
(1.00 – 16.00) 
IPD: pocket depth; SD: standard deviation 
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Table 2. Pocket depth, relative attachment level, and recession at baseline and at 24 weeks 
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(mm) 1.00 0.79 1.23 0.88 0.60 0.57 2
*
 
mITT: modified intent-to-treat; PP: per protocol 
N=number of implants 
IPD: implant pocket depth; RAL: relative attachment level; R: recession 
*
 Statistically significant difference between treatment groups, in a mixed linear model that 
used treatment as the fixed factor and patient and pocket as random effects, and which 






This article is protected by copyright. All rights reserved. 





Debridement + CHX 
chips 
Sub-gingival 
Debridement  p value 
N Percent N Percent 
≥ 1 mm 140 87.0 137 84 0.4575 
≥ 2 mm 95 59.0 77 47.2 0.0338
*
 
≥ 3 mm 37 23.0 32 19.6 0.4615 





Debridement + CHX 
chips 
Sub-gingival 
Debridement p value 
N Percent N Percent 
≥ 1 mm 113 86.3 111 84.1 0.6207 
≥ 2 mm 82 62.6 62 47.0 0.0109
*
 
≥ 3 mm 31 23.7 24 18.2 0.2744 
≥ 4 mm 7 5.3 6 4.5 0.7653 
IPD: Implant pocket depth 
mITT: modified intent-to-treat; PP: per protocol 
N: number of implants 
*
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Sub-gingival Debridement + 
CHX chips 
Sub-gingival Debridement  
p value 
N Mean ± SD Median N Mean ± SD Median 
5-6 mm 108 1.53 ± 0.96 2.00 112 1.39 ± 0.97 1.00 0.1185 
6-7 mm 94 1.93 ± 1.04 2.00 100  1.76 ± 1.08 2.00 0.2322 








N Mean ± SD Median N Mean ± SD Median 
5-6 mm 89 1.58 ± 0.97 2.00 88 1.33 ± 0.94 1.00 0.0153
*
 
6-7 mm    78 2.00 ± 1.06 2.00 83 1.77 ± 1.10 2.00 0.1012 
7-8 mm 42 2.21 ± 1.30 2.00 44 1.89 ± 1.38 2.00 0.3813 
IPD: Implant pocket depth 
mITT: modified intent-to-treat; PP: per protocol 
N: number of implants 
*
 Statistically significant difference between treatment groups, unadjusted [(Non-parametric Median 
test for independent samples were applied for analyzing of the difference in continuous changes 
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Table 5:  Effect of age and smoking habits on pocket depth change at week 24 
compared to baseline (post hoc evaluation) 
mITT population 
Parameters 




N Mean ± SD Median N Mean ± SD Median 
Age < 65 
Years 
83 1.73 ± 1.17 2.00 90 1.38 ± 1.13 1.00 0.0183
*
 
Age ≥ 65 
Years 
78 1.78 ± 1.09 2.00 73 1.73 ± 1.11 2.00 0.6332 
Non-
smokers 
146 1.82 ± 1.11 2.00 149 1.53 ± 1.14 1.00 0.0186
*
 
Smokers 15 1.13 ± 1.19 1.00 14 1.57 ± 1.09 1.50 0.4732 
PP population 
Parameters 




N Mean ± SD Median N Mean ± SD Median 
Age < 65 
Years 
68 1.74 ± 1.18 2.00 68 1.29 ± 1.16 1.00 0.0063
*
 
Age ≥ 65 
Years 
63 1.84 ± 1.07 2.00 64 1.75 ± 1.07 2.00 0.4643 
Non-
smokers 
118 1.86 ± 1.09 2.00 121 1.51 ± 1.13 1.00 0.0055
*
 
Smokers 13 1.08 ± 1.26 1.00 11 1.55 ± 1.21 1.00 0.5547 
IPD: Implant pocket depth 
mITT: modified intent-to-treat; PP: per protocol 
N: number of implants 
*
 Statistically significant difference between treatment groups, unadjusted [(Non-parametric Median 
test for independent samples were applied for analyzing of the difference in continuous changes 
between the treatment groups per time-point (week)]. 
